

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/559,982
<i>(Use as many sheets as necessary)</i>				Filing Date	February 2, 2006
				First Named Inventor	Ruggero Fariello
				Group Art Unit	1617
				Examiner Name	Sahar JAVANMARD
				Confirmation No.	6583
Sheet	1	of	3	Attorney Docket No.	373987-011US (102895)

U.S. PUBLISHED DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Publication Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A1	US-4,049,663		Harper <i>et al.</i>	09-20-1977
	A2	US-4,513,009		Roques <i>et al.</i>	04-23-1985
	A3	US-4,935,429		Dackis <i>et al.</i>	06-19-1990
	A4	US-4,970,200		Birkmayer <i>et al.</i>	11-13-1990
	A5	US-5,502,079		Dostert <i>et al.</i>	03-26-1996
	A6	US-6,306,903		Pevarello <i>et al.</i>	10-23-2001
	A7	US-6,500,867		Virkki <i>et al.</i>	12-31-2002

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ²	
		Office	Number			Kind Code (if known)	Yes
	B1	GB	1140748	01-22-1969	Thomas Leigh <i>et al.</i>		
	B2	WO	1990/14334	A1	Farmitalia Carlo Erba S.r.l.		
	B3	WO	1994/22808	A1	Farmitalia Carlo Erba S.r.l.		
	B4	WO	1997/05102	A1	Pharmacia & Upjohn S.P.A.		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Translation ²
					Yes No

Examiner Signature	/Sahar Javanmard/		Date Considered	09/13/2009
--------------------	-------------------	--	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/559,982
<i>(Use as many sheets as necessary)</i>				Filing Date	February 2, 2006
				First Named Inventor	Ruggero Fariello
				Group Art Unit	1617
				Examiner Name	Sahar JAVANMARD
				Confirmation No.	6583
Sheet	2	of	3	Attorney Docket No.	373987-011US (102895)

	C1	Bailey <i>et al.</i> , 1975, "The Mechanism of Action of Amantadine in Parkinsonism: A Review," <i>Arch. Int. Pharmacodyn. Ther.</i> , 216: 246-262		
	C2	Benedetti, S. <i>et al.</i> , 1994, "The Anticonvulsant FCE 26743 is a Selective and Short-Acting MAO-B Inhibitor Devoid of Inducing Properties Towards Cytochrome P450-dependent Testosterone Hydroxylation in Mice and Rats," <i>J. Pharm. Pharmacol.</i> 46:814-819		
	C3	Chase, Thomas, 1998, "The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson's Disease," <i>Drugs</i> , 55 (Suppl. 1): 1-9		
	C4	Chazot, P., 2001, "Salfinamide, Newron Pharmaceuticals," <i>Current Opinion in Invest. Drugs</i> , 2(6): 809-813		
	C5	Facca, A, <i>et al.</i> , 2003, "Differential Diagnosis of Parkinsonism," <i>Adv. Neurol</i> , 91:383-396		
	C6	Heikkila, R. <i>et al.</i> , 1984, "Protection Against the Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine by Monoamine Oxidase Inhibitors," <i>Nature</i> 311: 467-469		
	C7	Mann <i>et al.</i> , 1971, "Amantadine for Parkinson's Disease," <i>Neurology</i> , 21: 958-962		
	C8	Marjama-Lyons, J. <i>et al.</i> , 2001, "Parkinson's Disease: Update in Diagnosis and Symptom Management," <i>Geriatrics Aug</i> ; 56(8):24-25, 29-30, and 33-35		
	C9	Marsden <i>et al.</i> ; 1997, "Success and Problems of Long-Term Levodopa Therapy in Parkinson's Disease," <i>Lancet</i> 2-12-1997: 345-349		
	C10	Meldrum, B., 1994, "The Role of Glutamate in Epilepsy and Other CNS Disorders," <i>Neurology</i> , 44 (Supp. 8) 814-823		
	C11	Mytilineou, C. <i>et al.</i> , 1997, "L-Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor-Mediated Toxicity In Vitro," <i>J. Neurochem.</i> 68: 33-39		
	C12	Parkes, J. D. <i>et al.</i> , 1971, "Treatment of Parkinson's Disease with Amantadine and Levodopa,: <i>Lancet</i> , 21: 1083-1086		
	C13	Poewe, W., 1993, "Clinical Features, Diagnosis, and Imaging of Parkinsonian Syndromes," <i>Curr Opin Neurol Neurosurg</i> , Jun, 6(3):333-338		
	C14	Remington's Pharmaceutical Sciences 15th Edition, pages 1035-1038 and 1570-1580		
	C15	Salvati, P. <i>et al.</i> , 1999, "Biochemical and Electrophysiological Studies on the Mechanism of Action of PNU-151774E, A Novel Antiepileptic Compound," <i>Pharmacol. Exp. Ther.</i> 288:1151-1159		
	C16	Siderowf, A., 2001, "Parkinson's Disease: Clinical Features, Epidemiology, and Genetics," <i>Movement Disorders</i> , Aug, 19(3):565-578		
	C17	Sulkava, R. 2003, "Differential Diagnosis between Early Parkinson's Disease and Dementia with Lewy Bodies," <i>Adv. Neurol</i> , 91 :411-413		

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/559,982
<i>(Use as many sheets as necessary)</i>				Filing Date	February 2, 2006
				First Named Inventor	Ruggero Fariello
				Group Art Unit	1617
				Examiner Name	Sahar JAVANMARD
				Confirmation No.	6583
Sheet	3	of	3	Attorney Docket No.	373987-011US (102895)

	C18	Youdim, B. H. <i>et al.</i> , 1991, "New Directions in Monoamine Oxidase A and B Selective Inhibitors and Substrates," <i>Biochem. Pharmacol.</i> 41(2): 155-162		
--	------------	--	--	--

15106963.1.BUSINESS

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009
-----------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./